FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment

PURPOSE: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating lymphocyte (sTIL) or FcrR polymorphisms and survival among patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chae, Heejung, Yoo, Changhoon, Yoon, Jung-A, Lee, Hee Jin, Kim, Kyu-pyo, Kim, Jeong-Eun, Ahn, Jin-Hee, Jung, Kyung Hae, Gong, Gyungyub, Kim, Sung-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880965/
https://www.ncbi.nlm.nih.gov/pubmed/29628983
http://dx.doi.org/10.4048/jbc.2018.21.1.45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880965/
https://www.ncbi.nlm.nih.gov/pubmed/29628983
http://dx.doi.org/10.4048/jbc.2018.21.1.45

Ejemplares similares